Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Anemia is present years before myelodysplastic syndrome diagnosis: Results from the pre-diagnostic period

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The heterozygote state for β-thalassemia detrimentally affects health outcomes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Severe Aplastic Anaemia Working Party of the EBMT
Vis graf over relationer

We retrospectively analyzed the outcomes of 1837 adults and children with severe aplastic anemia (SAA) who underwent matched sibling donor (MSD) and matched unrelated donor (MUD) hemopoietic stem cell transplantation (HSCT) between 2000 and 2013. Patients were grouped by transplant conditioning containing either anti-thymocyte globulin (ATG) (n = 1283), alemtuzumab (n = 261), or no serotherapy (NS) (n = 293). The risks of chronic GvHD were significantly reduced when ATG or alemtuzumab were compared with NS (P = .021 and .003, respectively). Acute GVHD was significantly reduced in favor of alemtuzumab compared with ATG (P = .012) and NS (P < .001). By multivariate analysis, when compared with ATG, alemtuzumab was associated with a lower risk of developing acute (OR 0.262; 95% CI 0.14-0.47; P < .001) and chronic GVHD (HR 0.58; 95% CI 0.35-0.94; P = .027). OS was significantly better in ATG and alemtuzumab patients compared with NS (P = .010 and .025). Our data shows inclusion of serotherapy in MSD and MUD HSCT for patients with SAA reduces chronic GVHD and provides a survival advantage over patients not receiving serotherapy. Notably, alemtuzumab reduced the risk of acute and chronic GvHD compared with ATG and indicates that alemtuzumab might be the serotherapy of choice for MSD and MUD transplants for SAA.

OriginalsprogEngelsk
TidsskriftAmerican Journal of Hematology
Vol/bind94
Udgave nummer1
Sider (fra-til)80-86
Antal sider7
ISSN0361-8609
DOI
StatusUdgivet - jan. 2019

ID: 56566007